{"public_id":"cl_c8a0c2b95de260ad48998a5042504663","status":"active","superseded_by_public_id":null,"corpus_id":75311601,"text":"Clinical response persisted at 12 weeks in a larger proportion of cA2-treated patients than in the placebo group.","confidence":0.97,"paper":{"corpus_id":75311601,"title":"A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease","url":"https://sah.borca.ai/papers/75311601"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.97,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_1ba7956fde9d2e85f29784e22e7d88bc","name":"placebo","description":"An inactive comparator used to assess the effect of cA2.","types":["comparator"],"url":"https://sah.borca.ai/concepts/co_1ba7956fde9d2e85f29784e22e7d88bc"},{"public_id":"co_519269fc761d2421222a10b7de7c3605","name":"chimeric monoclonal antibody cA2","description":"A chimeric monoclonal antibody directed against tumor necrosis factor alpha and tested as a treatment for Crohn's disease.","types":["drug","therapeutic antibody"],"url":"https://sah.borca.ai/concepts/co_519269fc761d2421222a10b7de7c3605"},{"public_id":"co_7c99d0e1d114f57ba250e61938f6b49b","name":"clinical response","description":"The primary endpoint defined by a reduction of at least 70 points in the Crohn's Disease Activity Index without concomitant medication changes.","types":["outcome"],"url":"https://sah.borca.ai/concepts/co_7c99d0e1d114f57ba250e61938f6b49b"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_c8a0c2b95de260ad48998a5042504663"}